Cynata Therapeutics Limited (51S)
FSX
Real-time Data
06:00 AM
Day's Range
0.0005052 wk Range
0.00050Overview - 51S - Cynata Therapeutics Limited
Key Statistics
Valuation
Enterprise Value
-479.60K
P/E (Trailing)
‪-0.01‬
Price / Sales (TTM)
‪0.07‬
EV / EBITDA
‪0.10‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-456.59%‬
Return on Assets
‪-114.22%‬
Return on Equity
‪-325.34%‬
Ownership
Shares Outstanding
225.95M
Float
195.67M
Held by Insiders
‪24.97%‬
Held by Institutions
‪8.21%‬
Price stats
Beta
‪1.08‬
50-Day Avg
‪0.00050‬
200-Day Avg
‪0.1198‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 51S - Cynata Therapeutics Limited
Peers - 51S - Cynata Therapeutics Limited
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 51SFSXCynata Therapeutics Limited121.72KMarket Cap-17100.00%52-week change-0.01P/E (Trailing)‪0.00%‬Profit Margin
- ANLFSXAnalog Devices Inc.151.88BMarket Cap+35.24%52-week change43.41P/E (Trailing)‪29.78%‬Profit Margin
- 1AEFSXargenx SE52.93BMarket Cap+23.73%52-week change38.15P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt51.30BMarket Cap+24.85%52-week change36.06P/E (Trailing)‪32.26%‬Profit Margin
- 0QFFSXModerna Inc.50.90BMarket Cap+83.96%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.38.16BMarket Cap+25.45%52-week change136.57P/E (Trailing)‪30.74%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.64BMarket Cap+77.80%52-week change-29.52P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 51S - Cynata Therapeutics Limited
About
Cynata Therapeutics Limited is a clinical-stage biotechnology company focused on the development and commercialization of innovative stem cell and regenerative medicine therapies. The company’s proprietary Cymerus platform leverages induced pluripotent stem cell (iPSC) technology to produce mesenchymal stem cells for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
